PRPH

ProPhase Labs Inc

PRPH, USA

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides a broad range of COVID-19 related clinical diagnostic and testing services, comprising PCR testing for COVID-19, and Influenza A and B, as well as rapid antigen testing for COVID-19. It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

https://www.prophaselabs.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
PRPH
stock
PRPH

Prophase Labs Faces Unsealed Civil Action Disclosure MSN

Read more →
PRPH
stock
PRPH

ProPhase Labs Delays Q3 Filing Amid Reorganization MSN

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$13.8

Analyst Picks

Strong Buy

1

Buy

0

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.70

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-99.68 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-10.41 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-2,437.49 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

8.58

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 6.53% of the total shares of ProPhase Labs Inc

1.

Vanguard Group Inc

(0.9828%)

since

2025/06/30

2.

Vanguard Institutional Extnd Mkt Idx Tr

(0.6884%)

since

2025/07/31

3.

Geode Capital Management, LLC

(0.6236%)

since

2025/06/30

4.

HighTower Advisors, LLC

(0.5524%)

since

2025/06/30

5.

Quinn Opportunity Partners LLC

(0.5251%)

since

2025/06/30

6.

Fidelity Extended Market Index

(0.4227%)

since

2025/07/31

7.

Renaissance Technologies Corp

(0.332%)

since

2025/06/30

8.

XTX Topco Ltd

(0.2468%)

since

2025/06/30

9.

Susquehanna International Group, LLP

(0.2456%)

since

2025/06/30

10.

Chapin Davis Inc

(0.1926%)

since

2025/06/30

11.

Citigroup Inc

(0.1432%)

since

2025/06/30

12.

UBS Group AG

(0.1388%)

since

2025/06/30

13.

Belfund SICAV Belinvest Equity A USD Acc

(0.1204%)

since

2025/07/31

14.

State Street Corp

(0.1075%)

since

2025/06/30

15.

Virtu Financial LLC

(0.0973%)

since

2025/06/30

16.

Fidelity Series Total Market Index

(0.0972%)

since

2025/07/31

17.

TWO SIGMA SECURITIES, LLC

(0.0911%)

since

2025/06/30

18.

Bank of New York Mellon Corp

(0.0892%)

since

2025/06/30

19.

United Capital Management of KS

(0.0835%)

since

2025/06/30

20.

Spartan Extended Market Index Pool F

(0.0768%)

since

2025/07/31

21.

BlackRock Inc

(0.0675%)

since

2025/06/30

22.

Bank of America Corp

(0.0655%)

since

2025/06/30

23.

Northern Trust Corp

(0.0559%)

since

2025/06/30

24.

Extended Equity Market Fund K

(0.0545%)

since

2025/06/30

25.

Fidelity Total Market Index

(0.0535%)

since

2025/07/31

26.

Spartan Total Market Index Pool G

(0.0497%)

since

2025/07/31

27.

BKB Wealth Advisors, LLC

(0.0472%)

since

2025/06/30

28.

HPM Partners LLC

(0.0457%)

since

2025/06/30

29.

T. Rowe Price U.S. Equities Tr

(0.0406%)

since

2025/06/30

30.

Fidelity Nasdaq Composite Index

(0.0291%)

since

2025/07/31

31.

Vanguard Instl Ttl Stck Mkt Idx Tr

(0.0273%)

since

2024/12/31

32.

NT Ext Equity Mkt Idx Fd - NL

(0.0269%)

since

2025/06/30

33.

Northern Trust Extended Eq Market Idx

(0.0268%)

since

2025/06/30

34.

NT Ext Equity Mkt Idx Fd - L

(0.0268%)

since

2025/06/30

35.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0209%)

since

2025/06/30

36.

Vanguard U.S. Eq Idx £ Acc

(0.0098%)

since

2025/07/31

37.

State St US Extended Mkt Indx NL Cl C

(0.0089%)

since

2025/08/31

38.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0076%)

since

2025/06/30

39.

Extended Equity Market Fund M

(0.0069%)

since

2025/06/30

40.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0064%)

since

2024/12/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.1646

EPS Estimate

-0.11

EPS Difference

-0.0546

Surprise Percent

-49.6364%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Moderately Defensive(4)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
No Clear Moat(2.8)
GARP
Not Attractive for GARP(1)
Growth
Weak Growth Prospect(1)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(1.5)
Quality
Low Quality Business(1)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.